Klivira
Request demo

Optimizing Rexulti Prior Authorization for Oncology Supportive Care

Navigating Rexulti prior authorization for oncology patients requires precision and efficiency, especially when managing critical supportive care needs.

Oncology treatment pathways are complex, often extending beyond anti-cancer agents to include vital supportive care medications. For drugs like Rexulti, prescribed to manage conditions such as depression or agitation in cancer patients, prior authorization introduces administrative burdens that can delay essential care. Klivira helps health systems automate these intricate PA workflows, ensuring timely access to necessary treatments.

Rexulti's Role in Oncology Supportive Care

Rexulti (brexpiprazole) is an atypical antipsychotic used in oncology to manage psychiatric symptoms like depression (adjunctive treatment), agitation, or other neuropsychiatric complications frequently associated with cancer or its treatment. Its role is crucial in improving patient quality of life and treatment tolerance, making it a key component of comprehensive cancer care.

Prior Authorization Triggers for Supportive Care in Oncology

While Rexulti is not an oncolytic, it falls under the 'supportive care medications' category, which frequently triggers prior authorization in oncology. This category includes a broad range of medications for symptom management, pain, nausea, and psychiatric conditions, each requiring distinct PA processes to ensure medical necessity and appropriate utilization.

Essential Documentation for Rexulti PA in Oncology

  • Confirmed psychiatric diagnosis (e.g., Major Depressive Disorder, agitation) relevant to Rexulti's FDA-approved indications.
  • Documentation of prior psychotropic medication trials, including failures or contraindications, to address step therapy requirements.
  • Clinical rationale for Rexulti over alternative agents, detailing patient-specific symptoms, severity, and treatment goals.
  • Assessment of the patient's overall functional status (e.g., ECOG or Karnofsky score), where applicable, to support the need for supportive care.
  • Relevant comorbidities and a comprehensive medication reconciliation to assess potential drug interactions or contraindications.

Common Denial Reasons for Rexulti in Cancer Care

Prior authorization denials for Rexulti in oncology often stem from step therapy requirements, where payers mandate trials of less expensive or preferred alternatives before approving the requested agent. Other common reasons include insufficient documentation of prior treatment failures, a lack of clear medical necessity for Rexulti over other available options, or off-label use without adequate compendium support.

Navigating Pharmacy Benefit for Oral Supportive Medications

As an oral medication, Rexulti falls under the pharmacy benefit. This means prior authorization requests are typically submitted electronically (ePA) through Pharmacy Benefit Managers (PBMs) and their partners, such as CoverMyMeds or Surescripts. This process differs significantly from medical benefit prior authorizations for infused oncology drugs, which usually route via X12 278 transactions or payer-specific portals.

Klivira's Automation for Oncology Supportive Care PAs

Klivira's platform streamlines Rexulti prior authorization by integrating with EMRs to extract necessary clinical data, intelligently routing ePA requests to the correct pharmacy benefit managers, and tracking the status of multiple concurrent supportive care PAs. This reduces administrative burden, minimizes delays, and accelerates patient access to critical symptom management, allowing oncology teams to focus on direct patient care.

Frequently asked questions

Which NCCN guidelines apply to Rexulti use in oncology?

Rexulti is not typically covered by NCCN *oncology treatment* guidelines but may be referenced in NCCN *supportive care* guidelines (e.g., Distress Management, Palliative Care) for specific psychiatric indications. Payers often assess medical necessity based on FDA-approved indications and general psychiatric practice guidelines.

Is Rexulti typically considered a medical benefit or pharmacy benefit drug?

Rexulti is an oral medication, so it is processed under the pharmacy benefit. This means prior authorization requests are typically routed through the patient's Pharmacy Benefit Manager (PBM) and require electronic prior authorization (ePA) submissions.

What are the most common reasons for Rexulti PA denials in oncology patients?

Common denial reasons include failure to meet step therapy requirements (e.g., not trying generic alternatives first), insufficient documentation of prior treatment failures, or lack of clear medical necessity for Rexulti over other agents for the indicated condition.

How does Klivira handle the distinction between oncology treatment PAs and supportive care PAs like Rexulti?

Klivira's platform is designed to identify and route different types of prior authorizations based on drug type and benefit. For oral supportive care medications like Rexulti, it ensures proper ePA submission to PBMs, separate from medical benefit PAs for infused chemotherapy or biologics.

Does Rexulti PA require specific oncology-related documentation like tumor markers?

No, for Rexulti, the documentation focuses on the psychiatric diagnosis (e.g., MDD, agitation), prior treatment history, and clinical rationale for its use, not oncology-specific details like tumor markers or staging. However, the patient's overall oncology status (e.g., ECOG score) may be relevant to support the need for supportive care.

Related coverage

Other rexulti prior authorization by payer

Other rexulti prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo